Opportunities
Search

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines.  Distinctive Features: Funding from this award mechanism must support a clinical trial.·        Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies.·        Preliminary data are required.·        The inclusion of community-based participatory research (CBPR) approaches is required.·        The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.○       Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials.○       Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations.·        Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award. 

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Health Services Research Award (HSRA) intends to fund high-impact research that bridges the gap between research, practice and policy by building real-world evidence on how interventions, clinical practices/guidelines, or policies can be deployed to targeted populations at the appropriate time. In order to meet this intent, the mechanism supports health services research approaches. Distinctive Features: ·        The HSRA will support health services research approaches that include comparative effectiveness research; implementation of interventions, diagnostics and clinical practices/guidelines; and validation of data science insights. ·        Applications must include clinical research or clinical trials. Prospective or retrospective clinical research or clinical trials involving human subjects, human subject data/records, and human anatomical substances are allowed. ·        Preliminary data are required. ·        Basic, preclinical and animal research are prohibited. ·        For research prospectively enrolling human subjects, inclusion of community-based participatory research (CBPR) approaches is required. ·        Early-Career Investigator Partnering Option: This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.

Summary: The Translational Research Award (TRA) intends to accelerate the conversion of scientific findings into impactful clinical applications. The TRA prioritizes innovative approaches over purely iterative or incremental research. Submissions focusing on minor modifications to existing standards without the intent or potential to significantly improve clinical care or patient outcomes do not meet the intent of the mechanism.Distinctive Features: Basic research and clinical trials are prohibited. Preliminary data are required.·        For animal research, applications must describe the choice of model and its relevance to the human clinical condition.·        For research prospectively enrolling human subjects, the inclusion of community-based participatory research (CBPR) approaches is required.·        The Translational Research Award offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.○       Research Level 1: Supports the refinement of mature ideas and concepts into tangible and knowledge products positioned for further evaluation.○       Research Level 2: Supports the rigorous evaluation of tangible and knowledge products in preparation for first-in-human studies or clinical trials.·        Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award. 

This announcement invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. Projects supported by this NOFO are expected to generate data that elucidate mechanisms of toxicity of these agents, possible new manifestations of toxic exposures, and potential new targets for therapeutic development.

The U.S. Department of Agriculture (USDA), Agricultural Marketing Service (AMS), requests applications for the fiscal year (FY) 2026 Specialty Crop Multi-State Grant Program (SCMP). The SCMP supports collaborative multi-state partnerships to enhance the competitiveness of specialty crops through competitively funded projects. A multi-state partnership is a project that implements activities with measurable outcomes that benefit two or more U.S. States and/or Territories along with non-profit entities. The focus is to address regional or national level specialty crop issues, including, but not limited to, food safety, plant pests and disease, research, crop-specific projects addressing common issues, and marketing and promotion. Projects must enhance the competitiveness of U.S. or U.S. territory-grown specialty crops in either domestic or foreign markets.

The purpose of this NOFO is to enhance the capability of NCATS CTSA Program KL2 scholars and recipients of re-entry supplements supported by the CTSA Program to conduct research as they complete the transition to fully independent academic translational scientists. These R03 grants will support different clinical and translational science research projects, including pilot and feasibility studies; secondary data analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support submission of a subsequent R01, or equivalent, application.

The purpose of this Notice of Funding Opportunity (NOFO) is to seek applications for a Community Engagement Evaluation and Data coordination hub (CEED) for the Community-Based Participatory Research (CBPR) consortium: Advancing Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All. In addition to CEED, the ADAPT consortium will include separately funded CBPR projects, which will receive consultative services from the NIH Community Engagement Alliance Consultative Resource (CEACR) and join in the Science Collaborative for Health and Artificial Intelligence Reduction of Errors (SCHARE) platform for the overarching goal of promoting data use and transformational community engagement to optimize oral health for all people. The CEED hub will coordinate communications and various activities in support of CBPR projects and consortium functions in three domains:1) Data Planning, Consultation, and Technical Assistance for Research Methodology and Analytics; 2) Community Engagement Evaluation; and 3) ADAPT Infrastructure and Operational Support.

This Notice of Funding Opportunity (NOFO) solicits applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO is focused on sustaining operations and maintaining and evolving the scientific relevance of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that will be supported by companion ITCR NOFOs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the application must provide clear justification for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting close engagement between the resource and the targeted research community should be described.This NOFO invites applications to support the sustained operations of informatics technology resources that support a wide range of cancer research, including discovery biology, population studies,....

This Notice of Funding Opportunity (NOFO) invites applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO is focused on advancing emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. To be successful, proposed development plans must have a clear rationale for why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from driving cancer research projects as well as the broader user community throughout the development process must be included.This NOFO invites applications for the enhancement and dissemination of emerging, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research. The emphasis is on uniqueness and potential impact on cancer research. In addition, all projects proposed in response to this NOFO must involve the following ge...

The Historically Black Colleges and Universities - Excellence in Research (HBCU-EiR) program was established in response to direction provided in the Senate Commerce and Justice, Science and Related Agencies Appropriations Subcommittee Report (Senate Report 115-139), and is built on prior and continuing efforts by the National Science Foundation (NSF) to strengthen research capacity at Historically Black Colleges and Universities (HBCUs). This report provided guidance to NSF to establish the HBCU Excellence in Research program "to provide opportunities for both public and private HBCUs, particularly for those who have not been successful in larger NSF Research & Related Activities competitions, in order to stimulate sustainable improvement in their research and development capacity" (https://congress.gov/congressional-report/115th-congress/senate-report/139/1). EiR supports such capacity building by funding research projects aligned with NSF's research programs. The program aims to establish stronger connections between researchers at HBCUs and NSF's research programs.

The purpose of the Mathematical Sciences Postdoctoral Research Fellowships (MSPRF) is to support future leaders in mathematics and statistics by facilitating their participation in postdoctoral research environments thatwill have maximal impact on their future scientific development. There are two options for awardees: Research Fellowship and Research Instructorship. Awards will support research in areas of mathematics and statistics, including applications to other disciplines.

Summary: The fiscal year 2026 (FY26) Military Burn Research Program (MBRP) Discovery Award supports innovative, untested, groundbreaking research that provides new insights and explores early concepts in combat-relevant burn care that provide the foundation for future translational and/or clinical research. The proposed project may be exploratory, hypothesis-driven, or hypothesis-generating research, but must be novel and must be based on a strong scientific rationale and a well-developed study design. Distinctive Features: The focus of this award mechanism is innovation. Proposed research should lay the groundwork for future avenues of scientific investigation or product development in the area of combat-relevant burn care. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for groundbreaking future research projects.

Summary: Despite significant research investment in combat-relevant burn care, a disparity exists between newly discovered knowledge in burn care and its implementation into clinical practice across the distributed operational battlespace. The fiscal year 2026 (FY26) Military Burn Research Program (MBRP) Patient-Centered Research Award (PCRA) seeks to bridge the gap between research, practice, and policy by developing a knowledge base that provides clinically useful findings about how interventions, clinical practices, guidelines, tools, and policies can be deployed to burn patients in an austere, resource-limited, military operational environment.Distinctive Features: ·        This award mechanism must support clinical research or clinical trials but cannot support preclinical or animal research. Applications may propose prospective or retrospective research involving human subjects or human subject data.·        New for FY26: The FY26 PCRA offers a Mentorship Option at a higher funding level to support a synergistic relationship between an experienced researcher (Mentor) and one to two junior researchers (Mentees). The dual purpose of this award is to fund a primary research study addressing a critical gap in combat burn care while simultaneously fostering the development of the next generation of military burn research leaders.

Summary: The fiscal year 2026 (FY26) Military Burn Research Program (MBRP) Technology/Therapeutic Development Award (TTDA) is a burn-focused, product-driven award mechanism intended to provide support for the translation of promising preclinical findings into burn products for clinical application in an austere, resource-limited, distributed operational environment.Distinctive Features: The technology or therapeutic product(s) to be developed must be product-oriented (e.g., medical device, drug, or clinical practice guidelines involving a therapeutic or technology). The product(s) to be developed may be tangible or knowledge supporting the development of a tangible product and must address one or more of the FY26 MBRP TTDA focus areas. Knowledge products are allowable, provided that the knowledge is applicable to a technology or therapeutic under development. (A “knowledge product” is a non-tangible, non-materiel product that results from research with the potential to improve individual or public health.) ·        New for FY26: The FY26 MBRP TTDA offers a Mentorship Option at a higher funding level to support a synergistic relationship between an experienced researcher (Mentor) and one to two junior researchers (Mentees). The dual purpose of this award is to fund a primary research study addressing a critical gap in combat burn care while simultaneously fostering the development of the next generation of military burn research leaders.

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Clinical Research Award (CRA) supports clinical research that evaluates disease-specific factors and interventions. Research is intended to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Research addressing any and all types of arthritis is encouraged.Applications must address one of two FY26 ATRP CRA Focus Areas: Prevention and Early Diagnosis, or Treatment and Mitigation of Disease Progression/Burden.Distinctive Features: The FY26 ATRP CRA offers funding for two research levels. It is the responsibility of the applicant to select the level that aligns with the scope of the proposed research.• Research Level 1: Applications proposing clinical research or early-phase/pilot clinical trials, to include new or emerging research that is not ready for a full-scale randomized controlled clinical trial.• Research Level 2: Applications proposing a full-scale clinical trial.Applications should include a community collaborator (e.g., patient/care partner, community-based organization consultant) who will provide advice and consultation during study design and throughout study planning and implementation. The ATRP encourages a community collaborator for Research Level 1 applications and requires a community collaborator for Research Level 2 applications.Preliminary and/or published data are required.

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged.Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions.Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.

Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Idea Development Award (IDA) is to support conceptually innovative research that could lead to impactful discoveries or significant advancements that will accelerate progress toward reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or the quality of life. Applications should propose research that is conceptually innovative, introduces a new concept or question, challenges existing paradigms, approaches issues from a new perspective, or exhibits other uniquely creative qualities; and should not merely be a next logical step or an incremental advance on published data or ongoing research. Distinctive Features: A Career Development Option is available to eligible early-career investigators who propose to conduct impactful mechanism-relevant research under the mentorship of an experienced tick-borne disease researcher(s). Applications submitted under the IDA – Career Development Option (IDA-CDO) will be reviewed using separate, career development-specific evaluation criteria by a separate, dedicated peer review panel; and are subject to a lower cost limit than those submitted under the standard IDA.https://cdmrp.health.mil/pubs/press/2026/tbdrppreann

Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings.  https://cdmrp.health.mil/pubs/press/2026/tbdrppreann

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Career Development Award supports early-career, independent investigators and/or the transition of established investigators from other research fields to conduct innovative, high-impact ideas or early-phase, proof-of-principle clinical trials with the potential to have a major impact on autism.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Career Development Award Areas of Interest or provide justification that the proposed research addresses a critical problem, question, or need in autism.FY26 Career Development Award submissions with a pilot clinical trial component are required to include community collaborations to optimize research impact. Applications are expected to name at least one community partner (e.g., an Autistic individual or caregiver, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Clinical Trial Award Areas of Interest.Partnering Principal Investigator (PI) Option for Early-Career Investigator: The FY26 Clinical Trial Award mechanism is offering a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in autism clinical trial research.FY26 Clinical Trial Award submissions are required to include community collaborations to optimize research impact. Research teams are therefore required to establish and utilize effective and equitable collaborations and partnerships with community members to maximize the translational and impact potential of the proposed research. Applications to the FY26 ARP Clinical Trial Award are expected to name at least one community partner (e.g., A...

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for Autistic individuals. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Idea Development Award Areas of Interest or provide justification that the proposed research addresses a critical problem, question, or need in autism.Partnering Principal Investigator (PI) Option: The Partnering PI Option is structured so that two investigators, each of whom will be designated as a PI, will work synergistically on a single project. The results of this partnering project should significantly advance the research beyond what would be possible through individual efforts.

In 2016, the National Science Foundation (NSF) unveiled a set of “Big Ideas,” 10 bold, long-term research and process ideas that identify areas for future investment at the frontiers of science and engineering (see https://www.nsf.gov/news/special_reports/big_ideas/index.jsp). The Big Ideas represent unique opportunities to position our Nation at the cutting edge of global science and engineering leadership by bringing together diverse disciplinary perspectives to support convergence research. As such, when responding to this solicitation, even though proposals must be submitted to the Directorate for STEM Education (EDU) / Division of Equity for Excellence in STEM (EES), once received, the proposals will be managed by a cross-disciplinary team of NSF Program Directors. The INCLUDESInitiative is a comprehensive, national effort to enhance U.S. leadership in science, technology, engineering, and mathematics (STEM) discovery and innovation, focused on NSF’s commitment to ensuring accessibility and inclusivity in STEM fields, as communicated in the NSF Strategic Plan for Fiscal Years (FY) 2022 - 2026. The vision of the INCLUDES Initiative is to catalyze the STEM enterprise to work collaboratively for inclusive change, resulting in a STEM workforce that reflects the Nation’s population. More specifically, the INCLUDES Initiative seeks to motivate and accelerate collaborative infrastructure building to sustain systemic change to broaden participation in STEM fields at scale.Significant advancement of the INCLUDES Initiative's goalswill result in a new generation of STEM talent a...

Expected Impact:This Challenge looks to accelerate the development and uptake of clinically validated interventions that target the root cause of multiple age-related morbidities. It will: Deliver biotechnology-based interventions for healthy ageing Accelerate the implementation of personalised care in ageing based on molecular phenotyping​Provide recommendations for regulatory pathways addressing ageing as a target to inform developers, regulators, and other decision makers​, and Improve citizen literacy on longevity. Expected Outcome:Ambitious proposals put forward under this call will deliver:Proof-of-concepts (TRL3 completed) of biotechnology-based or pharmaceutical interventions that prevents or delays the onset of, or reverts, an age-related disease in a vertebrate model system, based on the hallmarks of ageing, taking into consideration practical challenges of implementing such an...

Expected Impact:The resulting portfolio will not only advance the scientific state-of-the-art but also build a robust, interoperable, and application-driven community, positioning Europe at the forefront of trustworthy cognitive AI. It should also lay the foundations for future European leadership in safe, human-centric cognitive AI, supporting sovereignty and competitiveness in key sectors. It will support the ambitions of the AI Act[1] and the European approach to Artificial Intelligence[2].Expected Outcome:Ambitious proposals put forward under this call will deliver: Models and/or architectures that handle multimodal data and knowledge, uncertainty, and can be trained and deployed with constrained computational resources Provable trustworthiness mechanisms ensuring explainability, transparency, fairness, risk evaluation, security and alignment with ethical and legal standards, includi...

Expected Impact:The main impacts of this Challenge will be:A new generation of energetically autonomous systems enabling new services that will improve the life of European citizens through applications in areas such as point of care diagnostics, smart sustainable cities etc.Supporting sustainability in energy consumption and production in keeping with the ambitions of RePowerEU[1] and the Green Deal[2], and Enhancement of the sustainability of IoTs and energetically autonomous systems in general. Expected Outcome:Ambitious proposals put forward under this call will:identify a new generation of advanced materials for miniaturised energy harvesting modules, andachieve TRL 4 for the resulting energetically autonomous systems. Portfolio ApproachThe portfolio of selected projects should lead to the development of a variety of advanced materials applied to a range of miniaturised energy harve...